- Home
- SKWD vs IMVT Comparison
SKWD vs IMVT Comparison
Compare SKWD & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKWD
- IMVT
- Stock Information
- Founded
- SKWD 2007
- IMVT 2018
- Country
- SKWD United States
- IMVT United States
- Employees
- SKWD N/A
- IMVT N/A
- Industry
- SKWD Property-Casualty Insurers
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKWD Finance
- IMVT Health Care
- Exchange
- SKWD Nasdaq
- IMVT Nasdaq
- Market Cap
- SKWD 2.4B
- IMVT 2.8B
- IPO Year
- SKWD 2023
- IMVT N/A
- Fundamental
- Price
- SKWD $54.84
- IMVT $16.81
- Analyst Decision
- SKWD Buy
- IMVT Buy
- Analyst Count
- SKWD 12
- IMVT 10
- Target Price
- SKWD $63.88
- IMVT $40.14
- AVG Volume (30 Days)
- SKWD 408.5K
- IMVT 1.4M
- Earning Date
- SKWD 08-04-2025
- IMVT 08-05-2025
- Dividend Yield
- SKWD N/A
- IMVT N/A
- EPS Growth
- SKWD 9.29
- IMVT N/A
- EPS
- SKWD 2.98
- IMVT N/A
- Revenue
- SKWD $1,213,759,000.00
- IMVT N/A
- Revenue This Year
- SKWD $18.33
- IMVT N/A
- Revenue Next Year
- SKWD $11.61
- IMVT N/A
- P/E Ratio
- SKWD $18.40
- IMVT N/A
- Revenue Growth
- SKWD 26.30
- IMVT N/A
- 52 Week Low
- SKWD $34.10
- IMVT $12.72
- 52 Week High
- SKWD $65.05
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- SKWD 36.47
- IMVT 60.99
- Support Level
- SKWD $55.78
- IMVT $15.80
- Resistance Level
- SKWD $58.18
- IMVT $16.46
- Average True Range (ATR)
- SKWD 1.76
- IMVT 0.72
- MACD
- SKWD -0.43
- IMVT 0.05
- Stochastic Oscillator
- SKWD 23.33
- IMVT 87.21
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.